To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
The New England Journal of Medicine
Congratulations to Jeffrey Zonder, M.D., leader of the Multiple Myeloma and Amyloidosis Multidisciplinary Team at Karmanos Cancer Institute. Dr. Zonder co-authored a paper that was recently published by The New England Journal of Medicine. Titled “Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis,” the paper includes the results of a randomized trial, which led to the first FDA approval of any therapy for AL amyloidosis: Daratumumab-FasPro + CyBorD. Three former Karmanos fellows are also co-authors.
Click here to view the article.